



## Nanoparticle-Based Vaccine Development

Guest Editors:

**Dr. Yashdeep Phanse**

Director of Scientific Operations,  
Pan Genome Systems, 505 S.  
Rosa Rd, Madison, WI 53719, USA

**Prof. Dr. Adel M. Talaat**

Department of Pathobiological  
Sciences, School of Veterinary  
Medicine, University of  
Wisconsin, Madison, WI 53706,  
USA

Deadline for manuscript  
submissions:

**closed (31 January 2023)**

### Message from the Guest Editors

Dear Colleagues,

Vaccination has been one of the most efficacious ways to prevent and/or treat infectious diseases in humans and animals. Traditional vaccination approaches such as live or inactivated vaccines have disadvantages such as reversal to virulence, safety concerns, and need for multiple doses to name a few. The newer strategies using recombinant antigens or nucleic acids (DNA/mRNA) addresses many of the challenges mentioned above, however, they need either a delivery vehicle or an adjuvant, or a combination of to be effective. In this respect, nanoparticles have successfully been used as delivery agents for nucleic acid or subunit-based vaccines.

In this special issue focused on “Nanoparticle based vaccines”, we are pleased to invite original research articles or reviews related to this field. The topics include nanoparticle-based vaccines for human and animal health. The issue will cover animal vaccines including livestock, companion animals, and aquaculture.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)